Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)
CHS-0214-02
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Rheumatoid Arthritis and Inadequate Response to Treatment With Methotrexate
1 other identifier
interventional
647
12 countries
141
Brief Summary
This is a two part study comparing CHS-0214 to Enbrel in patients with active rheumatoid arthritis and an inadequate response with Methotrexate (MTX) who are naive to biologic therapies. Pt.1 is a 24-week randomized, double-blind, active-control, parallel-group, multi-center global study. The primary end point is 20% improvement in American College of Rheumatology criteria (ACR-20) at week 24. Comparing CHS-0214 to Enbrel for efficacy and safety. Pt. 2 is an open-label single arm study in which patients with at least an ACR-20 response receive CHS-0214. Continued response and safety will be evaluated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3 rheumatoid-arthritis
Started May 2014
141 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 14, 2014
CompletedFirst Posted
Study publicly available on registry
April 16, 2014
CompletedStudy Start
First participant enrolled
May 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2016
CompletedResults Posted
Study results publicly available
June 26, 2019
CompletedJune 26, 2019
June 1, 2019
1.4 years
April 14, 2014
December 18, 2018
June 7, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
ACR-20 - 20% Improvement According to American College of Rheumatology Criteria
The primary efficacy endpoint in Part 1 was the percentage of subjects who achieved ACR20 (20% improvement according to American College of Rheumatology criteria) at week 24 compared to baseline (last non-missing value prior to first dose). Subjects were considered an ACR20 responder if when compared to baseline (last non-missing value prior to first dose), they achieved a 20% decrease in SJC (Swollen joint count), 20% decrease in TJC (Tender joint count), and 20% improvement in 3 of the following 5 measures: high sensitivity C reactive protein(hs-CRP), Health Assessment Questionnaire Disability Index(HAQ-DI), subjects global assessment of pain(SPA, VAS), subject's global assessment of disease activity(SGA-VAS), physician's global assessment of disease activity(PGA-VAS)
24-weeks
Secondary Outcomes (6)
ACR20 - (20% Improvement According to American College of Rheumatology Criteria) at Weeks 4, 8, 12, and 18
Weeks 4, 8, 12 and 18
Summary of Change in Tender Joint Count (TJC) by Study Visit
Weeks 4,8,12,18,24,28,36,48
Summary of Change in Swollen Joint Count (SJC) by Study Visit
Weeks 4,8,12,18,24,28,36,48
Summary of Change in Health Assessment Questionnaire - Disability Index (HAQ-DI) by Study Visit
Weeks 4,8,12,18,24,28,36,48
Summary of Change in Subject's Pain Assessment - Visual Analog Scale (SPA-VAS) by Study Visit
Weeks 4,8,12,18,24,28,36,48
- +1 more secondary outcomes
Study Arms (2)
Enbrel (etanercept)
ACTIVE COMPARATOREnbrel 50mg weekly times 24 weeks.
CHS-0214
EXPERIMENTALCHS-0214 50mg weekly times 24 weeks.
Interventions
Eligibility Criteria
You may qualify if:
- Male or female adults
- RA (Rheumatoid Arthritis) diagnosis for 6 months
- On stable dose of MTX of 8mg to 25mg per week
- Active disease: greater than 6 tender joints, greater than 6 swollen joints, C-reactive protein (CRP) greater than or equal to 0.5mg/dL, and disease activity score (DAS) with 28 joints (DAS28-CRP(4)) greater than or equal to 3.2
You may not qualify if:
- Use of prednisone greater than 10mg/day
- Use of greater than one non-steroidal anti-inflammatory drug (NSAID)
- Use of biologic therapies for any cause
- Chemistry and hematology values outside protocol specified range
- Positive QuantiFERON-tuberculosis (TB) Gold Test
- Evidence of active lung disease on chest x-ray
- Major systemic infections
- Presence of significant comorbid conditions
- Known allergy to latex
- Women who are pregnant or nursing
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Coherus Oncology, Inc.lead
- Daiichi Sankyo Co., Ltd.collaborator
Study Sites (141)
Elite Clinical Studies
Phoenix, Arizona, 85018, United States
Arizona Research Center
Phoenix, Arizona, 85020, United States
NEA Baptist Clinic
Jonesboro, Arkansas, 72401, United States
Dream Team Clinical Research
Anaheim, California, 92801, United States
Advanced Medical Research
Lakewood, California, 90712, United States
Pro Health Partners
Long Beach, California, 90808, United States
St. Joseph Hospital of Orange
Orange, California, 92868, United States
Desert Medical Advances
Palm Desert, California, 92260, United States
Kaiser Permanente - CA
Richmond, California, 94801, United States
Med Investigators, Inc
Roseville, California, 95661, United States
Troum Medical Associates
Santa Monica, California, 90404, United States
Inland Rheumatology Clinical Trials Inc
Upland, California, 91786, United States
IMMUNOe International Research Centers
Centennial, Colorado, 80112, United States
Hope Clinical Research
Kissimmee, Florida, 34741, United States
Advanced Medical Research, Inc
Orlando, Florida, 32804, United States
Allergy & Rheumatology Associates LLC
St. Petersburg, Florida, 33708, United States
HealthPoint Medical Group
Tampa, Florida, 33614, United States
Bluegrass Community Research, Inc
Lexington, Kentucky, 40504, United States
The Center for Rheumatology and Bone Research
Wheaton, Maryland, 20902, United States
Clinical Pharmacology Study Group
Worcester, Massachusetts, 01605, United States
St. Louis Center for Clinical Research
St Louis, Missouri, 63128, United States
Arthritis Center of Nebraska
Lincoln, Nebraska, 68516, United States
Pacific Arthritis Center Medical Group
Omaha, Nebraska, 68198, United States
Rheumatoid Arthritis Investigational Network
Omaha, Nebraska, 68198, United States
North Shore University Hospital
Great Neck, New York, 11021, United States
Montefiore Medical Center
The Bronx, New York, 10467, United States
DJL Clinical Research
Charlotte, North Carolina, 28210, United States
PMG Research of Wilmington LLC
Wilmington, North Carolina, 28401, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, 16635, United States
Low Country Rheumatology
Charleston, South Carolina, 29406, United States
Arthritis Clinic
Jackson, Tennessee, 38305, United States
Texas Physicians Medical Research Group
Arlington, Texas, 76015, United States
Metroplex Clinical Research Center
Dallas, Texas, 75231, United States
Pioneer Research Solutions Inc
Houston, Texas, 77036, United States
Arthritis Northwest Rheumatology PLLC
Spokane, Washington, 99204, United States
Rheumatic Disease Center
Glendale, Wisconsin, 53217, United States
Gundersen Lutheran Medical Center
Onalaska, Wisconsin, 54650, United States
Brest Regional Clinical Hospital
Brest, 224027, Belarus
Grodno Regional Clinical Hospital
Grodno, 230017, Belarus
Gomel Regional Clinical Hospital
Homyel, 246029, Belarus
City Clinical Hospital #1 - Belarus
Minsk, 220013, Belarus
City Clinical Hospital #9 - Belarus
Minsk, 220116, Belarus
Vitebsk Regional Clinical Hospital
Vitebsk, 210037, Belarus
Hôpital Michallon - CHU de Grenobl
Grenoble, 38434, France
CHU Bicetre
Le Kremlin-Bicêtre, 94275, France
Centre Hospitalier Regional D'Orleans
Orléans, 45067, France
Hopital Cochin-Saint Vincent de Paul
Paris, 75014, France
Hopital de Saint Etienne
Saint-Etienne, 42055, France
Asklepios Klinikum Bad Abbach
Bad Abbach, 93077, Germany
Klinische Forschung Dresden GmbH
Dresden, 01069, Germany
Center of Innovative Diagnostics and Therapeutics Rheumatology/Immunology
Frankfurt, 60528, Germany
Universitätsmedizin Göttingen
Göttingen, 37075, Germany
SMO.MD GmbH - Zentrum fuer klinische Studien
Magdeburg, 39112, Germany
St. Rokus Hospital, BAJA
Baja, 6500, Hungary
DRC Gyogzszervizsgalo Kozpont
Balatonfüred, 8230, Hungary
Orszagos Reumatologiai es Fizioterapias Intezet
Budapest, 1023, Hungary
Qualiclinic Kft
Budapest, 1036, Hungary
Békés Megyei Pándy Kálmán Kórház
Gyula, 5700, Hungary
University of Szeged, Faculty of Medicine
Szeged, 6725, Hungary
Rakoczi Ferenc Korhaz-CRU Hungary (KFT)
Szikszó, 3800, Hungary
Rambam Medical Center
Haifa, 3109601, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, 64239, Israel
Sheba Medical Center
Tel Litwinsky, 52621, Israel
Assaf Harofeh Medical Center
Ẕerifin, 70300, Israel
Nagoya University Hospital
Nagoya, Aichi-ken, 466-8560, Japan
Inoue Hospital
Takasaki-shi, Gunma, 370-0053, Japan
Hiroshima Clinic
Nishiku, Hiroshimashi, 733-0032, Japan
Izumi Himawari Clinica
Sendai, Miyagi, 981-3135, Japan
Miyashita Rheumatology Clinic
Omura-shi, Nagasaki, 856-0836, Japan
Japanese Red Cross Okayama Hospital
Okayama, Okayama-ken, 700-8607, Japan
Japanese Red Cross Nagoya Daiichi Hospital
Aichi, 453-8511, Japan
Yamada Rheumatology Clinic
Ehime, 790-0905, Japan
University of Occupational and Environmental Health Hospital
Fukuoka, 807-8556, Japan
Kondo Clinic for Rheumatism and Orthopaedics
Fukuoka, 810-0001, Japan
Medical Co. LTA PS Clinic
Fukuoka, 812-0025, Japan
Shono Rheumatism Clinic
Fukuoka, 814-002, Japan
St Mary;s Hospital
Fukuoka, 830-8543, Japan
Hiroshima Rheumatology Clinic
Hiroshima, 730-0017, Japan
Medical Corporation Nakayama Clinic
Hyōgo, 650-0044, Japan
Matsubara Mayflower Hospital
Hyōgo, 673-1462, Japan
Eiraku Clinic
Kagoshima, 890-0055, Japan
Izumihara Rheumatic and Medical Clinic
Kagoshima, 890-0067, Japan
Kawasaki Rheumatism and Internal Medicine Clinic
Kanagawa, 212-0014, Japan
Kumamoto Orthopaedic Hospital
Kumamoto, 862-0976, Japan
Munakata Yasuhiko Clinic
Miyagi, 980-6166, Japan
Yu-Family Clinic
Miyagi, 981-0112, Japan
Sendai Taihaku Hospital
Miyagi, 982-0032, Japan
Kai Clinic
Miyazaki, 880-0053, Japan
Zenjinkai Shimin no Mori Hospital
Miyazaki, 880-0122, Japan
Komagamine Orthopaedic Rheumatic Clinic
Morioka Iwate, 020-0034, Japan
Nagasaki Medical Hospital of Rheumatology
Nagasaki, 850-0832, Japan
Nagasaki University Hospital
Nagasaki, 852-8501, Japan
SaSebo Chuo Hospital
Nagasaki, 857-1195, Japan
Yoshida Orthopaedic and Rheumatology Clinic
Numakunai, 020-0015, Japan
Rinku Hashimoto Rheumatology Orthopedics
Osaka, 598-0048, Japan
Oribe Clinic of Rheumatism and Medicine
Ōita, 870-0823, Japan
Otsuka Clinica of Rheumatism and Medicine
Ōita, 870-1155, Japan
Koshigaya Municipal Hospital
Saitama, 343-8577, Japan
Medical Corporation Kojyokai Hirose Clinic
Saitama, 359-1111, Japan
Hokkaido Medical Center for Rheumatic Diseases
Sapporo, 063-0811, Japan
St. Luke's International Hospital
Tokyo, 104-8560, Japan
Keio University Hospital
Tokyo, 160-8582, Japan
Miyasato Clinic
Yamaguchi, 745-0824, Japan
Tokito Clinic Rheumatology and Orthopaedics, Surgery
Yamaguchi, 752-0976, Japan
Centrum Kliniczno Badawcze
Elblag, 82-300, Poland
Synexus Polska Sp. z o.o. Oddzial w Gdyni
Gdynia, 81-384, Poland
Mazowieckie Centrum Badan Klinicznych (MCBK) SC
Grodzisk Mazowiecki, 05825, Poland
Synexus Polska Sp. z o.o. Oddzial w Katowicach
Katowice, 40-040, Poland
Centrum Terapii Wspólczesne
Kodz, 90242, Poland
NZOZ Lecznica MAK-MED
Nadarzyn, 05-830, Poland
Profmedicus sp. z o.o
Olsztyn, 10696, Poland
Centrum Medyczne SYNEXUS Poznan
Poznan, 60702, Poland
Prywatna Praktyka Lekarska Prof UM dr hab. Med. Pawel Hrycaj
Poznan, 61-639, Poland
Synexus Polska Sp. z o.o. Oddzial w Warszawie
Warsaw, 01-192, Poland
Centrum Medyczne AMED
Warsaw, 01518, Poland
Biogenes NZOZ
Wroclaw, 53-224, Poland
Synexus Polska Sp. z o.o
Wroclaw, 53-413, Poland
Krasnoyarsk Medical Academy
Krasnoyarsk, 660022, Russia
State Healthcare Institution of Moscow City Clinical Hospital #15 n.a. O.M. Filatov
Moscow, 111539, Russia
Practicheskaya Meditsina, Ltd
Moscow, 115404, Russia
Republican Hospital n.a. V.A. Baranov
Petrozavodsk, 185019, Russia
Medical Research Institute, LLC
Saint Petersburg, 196084, Russia
St. Petersburg State Healthcare Institution "Consultative diagnostic center #85
Saint Petersburg, 198260, Russia
Smolensk State Medical University (SSMU)
Smolensk, 214019, Russia
Municipal Healthcare Institution "Emergency Clinical Hospital n.a. N.V. Soloviev
Yaroslavl, 150003, Russia
Sverdlovsk Regional Clinical Hospital #1
Yekaterinburg, 620102, Russia
MBI "Central City Clinical Hospital #6
Yekaterinburg, 620149, Russia
Dr CI Louw
Cape Town, 7500, South Africa
Dr S Nayiager
Durban, 4001, South Africa
Wits Donald Gordon Clinical Trial Site
Johannesburg, 2193, South Africa
Drs Dindar and Partners
Mpumalanga, 2330, South Africa
Private Practice - Cathy Spargo
Pinelands, 7405, South Africa
Jakaranda Hospital Pretoria
Pretoria, 0002, South Africa
Emmed Research
Pretoria, 0084, South Africa
Winelands Rheumatology Centre
Stellenbosch, 7600, South Africa
Hospital Universitario Ramon y Cajal
Madrid, 28034, Spain
Hospital La Paz
Madrid, 28046, Spain
Hospital Regional Universitario de Málaga
Málaga, 29009, Spain
Royal Sussex County Hospital
Brighton, BN25PE, United Kingdom
Harrogate District NHS Foundation Trust
Harrogate, HG27SX, United Kingdom
Wirral University Teaching Hospital NHS Foundation Trust
Merseyside, CH495PE, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Barbara K. Finck, MD Chief Medical Officer
- Organization
- Coherus BioSciences, Inc
Study Officials
- STUDY DIRECTOR
Barbara K Finck, M.D.
Coherus Oncology, Inc.
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 14, 2014
First Posted
April 16, 2014
Study Start
May 1, 2014
Primary Completion
October 1, 2015
Study Completion
May 1, 2016
Last Updated
June 26, 2019
Results First Posted
June 26, 2019
Record last verified: 2019-06